Powered by

Sorrento Therapeutics Autologous Anti-CEA CAR-T Cell Therapy for Liver Metastases Demonstrates Therapeutic Activity in Stage IV Pancreas Cancer in a Phase 1b HITM-SURE Trial (NCT02850536)

Mar 05, 2018 - GlobeNewswire

SAN DIEGO, March 05, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE) ("Sorrento"), cellular therapy focused subsidiary, TNK Therapeutics, Inc. ("TNK"), and Surefire Medical, Inc., announced today initial results from the Hepatic ImmunoTherapy for Metastases-Surefire, or HITM-SURE (NCT02850536), a Phase 1b single arm trial testing its autologous anti-CEA CAR-T cells administered regionally by hepatic artery infusion (HAI) via pressure directed microvalve infusion (MVI) techno...